Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs acarbose on endothelial function in type 2 diabetes
2009-016053-18Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) and endothelial dysfunction (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Endothelium-dependent vasodilatation and Endothelium-independent vasodilatation. Started Oct 2009; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)endothelial dysfunction
Beyond the preview
Go deeper on 2009-016053-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016053-18.